LFCR Financials

Income Statement
MetricQ3 2026Q1 2027Q4 2026Q2 2026Q3 2025
Revenue
25.3M
-25.9%
34.2M
+47.3%
23.2M
-25.4%
31.1M
+0.0%
31.1M
Cost of Revenue
18.5M
-16.3%
22.1M
+17.9%
18.7M
-19.7%
23.3M
+0.0%
23.3M
Gross Profit
6.8M
-43.5%
12.1M
+170.6%
4.5M
-42.7%
7.8M
+0.0%
7.8M
Operating Expenses
7.7M
-18.8%
9.5M
+4.1%
9.1M
-15.9%
10.9M
+0.0%
10.9M
R&D
1.4M
-7.5%
1.5M
+26.3%
1.2M
-38.0%
2.0M
+0.0%
2.0M
SG&A
6.3M
-21.0%
8.0M
+0.7%
7.9M
-11.0%
8.9M
+0.0%
8.9M
Operating Income
-894000
-134.8%
2.6M
+154.9%
-4672000
-52.3%
-3067000
+0.0%
-3067000
EBITDA
-894000
-134.8%
2.6M
+208.7%
-2362000
-117.5%
-1086000
+64.6%
-3067000
Net Income
-40084000
-551.1%
-6156000
+58.9%
-14980000
-49.9%
-9991000
+0.0%
-9991000
EPS (Basic)
$-1.08
-468.4%
$-0.19
+55.8%
$-0.43
-48.3%
$-0.29
+0.0%
$-0.29
EPS (Diluted)
$-1.08
-468.4%
$-0.19
+55.8%
$-0.43
-48.3%
$-0.29
+0.0%
$-0.29
Shares (Diluted)
37.8M
+0.7%
37.6M
+0.3%
37.5M
+0.2%
37.4M
+0.0%
37.4M
Lifecore Biomedical (LFCR) — Financials